Respiratory Inhaler Devices MarketThe global respiratory inhaler devices market, valued at USD 37,258.5 million in 2023, is projected to grow at a compound annual growth rate (CAGR) of 4.90%, reaching ...
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.
In a recent study published in the JAMA, a group of researchers evaluated and compared the effectiveness of short-acting β agonists (SABA) alone versus SABA combined with inhaled corticosteroids ...
Medications are usually the first line of treatment for bipolar disorder. Mood stabilizers, antidepressants, and benzodiazepines may be part of the management plan on their own or in combination ...